Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 12/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046842 | 0.86 | CYP17A1 (0.57) | CYP17A1CYP26A1KDM4ECYP19A1 | |
| SCHEMBL14837761 | 0.84 | CYP17A1 (0.49) | CYP17A1CYP26A1KDM4E | |
| SCHEMBL14837689 | 0.80 | CYP17A1 (0.48) | CYP17A1CYP19A1 | |
| SCHEMBL13720325 | 0.77 | KDM4E (0.54) | CYP17A1CYP26A1KDM4E | |
| SCHEMBL5124051 | 0.75 | CYP26A1 (0.56) | CYP26A1KDM4E | |
| SCHEMBL5566011 | 0.75 | CYP17A1 (0.40) | CYP17A1CYP26A1 | |
| Hydrochloric Acid SCHEMBL4056640 | 0.74 | NPSR1 (0.46) | CYP17A1CYP26A1KDM4E | |
| SCHEMBL4053250 | 0.73 | CYP17A1 (0.42) | CYP17A1CYP19A1 | |
| SCHEMBL4056699 | 0.73 | CYP17A1 (0.57) | CYP17A1CYP26A1KDM4E | |
| SCHEMBL4987125 | 0.71 | CYP26A1 (0.73) | CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | claimed |
| EP-1037880-B1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | CYP17A1 304/4885CYP26A1 27/4885KDM4E 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.